146 related articles for article (PubMed ID: 38265675)
21. Hepatocellular Carcinoma Tumor Dose Response After
Kappadath SC; Mikell J; Balagopal A; Baladandayuthapani V; Kaseb A; Mahvash A
Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):451-461. PubMed ID: 30191875
[TBL] [Abstract][Full Text] [Related]
22. [Nuclear medicine techniques for selective internal radiotherapy of liver cancer].
Staanum PF; Arveschoug AK; Kramer SM; Nielsen JE; Nielsen DT; Ott P; Grønbæk H; Villadsen GE
Ugeskr Laeger; 2017 Jan; 179(1):. PubMed ID: 28074772
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the Adverse Event Profile of TheraSphere
Kallini JR; Gabr A; Thorlund K; Balijepalli C; Ayres D; Kanters S; Ebrahim S; Mills E; Lewandowski RJ; Salem R
Cardiovasc Intervent Radiol; 2017 Jul; 40(7):1033-1043. PubMed ID: 28246879
[TBL] [Abstract][Full Text] [Related]
24. Uncomplicated 90Y Selective Internal Radio Therapy in a Patient With Hepatocellular Carcinoma After Arterial and Portal Vein Embolizations.
van der Pol J; de Vos-Geelen J; Bucerius J; Mitea C; van der Leij C
Clin Nucl Med; 2018 Mar; 43(3):180-182. PubMed ID: 29389772
[TBL] [Abstract][Full Text] [Related]
25. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
[TBL] [Abstract][Full Text] [Related]
27. Hepatic radioembolization with Yttrium-90 glass microspheres for treatment of primary liver cancer.
Cao X; He N; Sun J; Tan J; Zhang C; Yang J; Lu T; Li J
Chin Med J (Engl); 1999 May; 112(5):430-2. PubMed ID: 11593513
[TBL] [Abstract][Full Text] [Related]
28. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
Ricke J; Klümpen HJ; Amthauer H; Bargellini I; Bartenstein P; de Toni EN; Gasbarrini A; Pech M; Peck-Radosavljevic M; Popovič P; Rosmorduc O; Schott E; Seidensticker M; Verslype C; Sangro B; Malfertheiner P
J Hepatol; 2019 Dec; 71(6):1164-1174. PubMed ID: 31421157
[TBL] [Abstract][Full Text] [Related]
29. (90)Y-glass microspheres for hepatic neoplasia.
Mahnken AH
Future Oncol; 2015; 11(9):1343-54. PubMed ID: 25952780
[TBL] [Abstract][Full Text] [Related]
30. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres.
Garin E; Rolland Y; Laffont S; Edeline J
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):559-75. PubMed ID: 26338177
[TBL] [Abstract][Full Text] [Related]
31. Verification Study of Residual Activity Measurements After Yttrium-90 Radioembolization with Glass Microspheres.
Ebbers SC; Kunnen B; van Nierop BJ; Bemelmans JLM; Krijger GC; Lam MGEH; Braat AJAT
Cardiovasc Intervent Radiol; 2020 Sep; 43(9):1378-1383. PubMed ID: 32435831
[TBL] [Abstract][Full Text] [Related]
32. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group.
Salem R; Padia SA; Lam M; Chiesa C; Haste P; Sangro B; Toskich B; Fowers K; Herman JM; Kappadath SC; Leung T; Sze DY; Kim E; Garin E
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):328-343. PubMed ID: 36114872
[TBL] [Abstract][Full Text] [Related]
33. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
Walton M; Wade R; Claxton L; Sharif-Hurst S; Harden M; Patel J; Rowe I; Hodgson R; Eastwood A
Health Technol Assess; 2020 Sep; 24(48):1-264. PubMed ID: 33001024
[TBL] [Abstract][Full Text] [Related]
34. Current role of selective internal irradiation with yttrium-90 microspheres in the management of hepatocellular carcinoma: a systematic review.
Lau WY; Lai EC; Leung TW
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):460-7. PubMed ID: 20888138
[TBL] [Abstract][Full Text] [Related]
35. High quality imaging and dosimetry for yttrium-90 (
Duan H; Khalaf MH; Ferri V; Baratto L; Srinivas SM; Sze DY; Iagaru A
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2426-2436. PubMed ID: 33443618
[TBL] [Abstract][Full Text] [Related]
36.
Tabotta F; Gnesin S; Dunet V; Ponti A; Digklia A; Boughdad S; Schaefer N; Prior JO; Villard N; Tsoumakidou G; Denys A; Duran R
Sci Rep; 2023 Aug; 13(1):13118. PubMed ID: 37573346
[TBL] [Abstract][Full Text] [Related]
37. Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma.
Muszbek N; Remak E; Evans R; Brennan VK; Colaone F; Shergill S; Mullan D; Ross PJ
Future Oncol; 2021 Mar; 17(9):1055-1068. PubMed ID: 33222542
[No Abstract] [Full Text] [Related]
38. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival.
Salem R; Lewandowski RJ; Atassi B; Gordon SC; Gates VL; Barakat O; Sergie Z; Wong CY; Thurston KG
J Vasc Interv Radiol; 2005 Dec; 16(12):1627-39. PubMed ID: 16371529
[TBL] [Abstract][Full Text] [Related]
39. Predicting the net administered activity in
Henry EC; Lopez B; Mahvash A; Thomas MA; Kappadath SC
Med Phys; 2023 Nov; 50(11):7003-7015. PubMed ID: 37272198
[TBL] [Abstract][Full Text] [Related]
40. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers.
Kennedy AS; Nutting C; Coldwell D; Gaiser J; Drachenberg C
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1552-63. PubMed ID: 15590187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
